利用疾病预后指导前列腺癌主动监测的纳入标准、定义标准化终点和分层随访
研究将剑桥预后分组(CPG)模型应用于英国和瑞典前列腺癌队列,检验CPG2和3与CPG1在保守治疗或 upfront 治疗下的前列腺癌死亡率差异,并在英国和西班牙主动监测(AS)队列中验证以进展至CPG3为硬终点及预测因素。结果显示CPG模型可区分前列腺癌死亡风险,PSA密度≥0.15 ng/mL/mL和诊断时CPG2可预测进展,作者认为利用疾病预后可合理指导AS的纳入标准、终止触发和风险分层管理。
要点
- CPG模型可区分保守治疗或 upfront 治疗下前列腺癌死亡风险。
- PSA密度≥0.15 ng/mL/mL和诊断时CPG2是进展至CPG3的预测因素。
- 作者认为利用疾病预后可合理指导主动监测的纳入标准、终止触发和风险分层管理。
核心结论
- 利用疾病预后可合理指导主动监测的纳入标准、终止触发和风险分层管理。
研究设计与样本
- 将五层CPG分类模型(基于PSA、Grade Group和分期预测癌症生存结局)应用于英国(n=3659)和瑞典(n=27942)前列腺癌队列,比较CPG2和3与CPG1在保守治疗或 upfront 治疗下的前列腺癌死亡率差异。
- 将CPG模型应用于英国当代AS队列(n=133,基线对疾病负荷进行优化表征),识别真正预后进展的预测因素,并在西班牙外部AS队列(n=143)中重新验证。
主要发现
- 英国队列10年前列腺癌死亡率:CPG1为2.3%,CPG2治疗组1.5% vs 未治疗组3.5%,CPG3治疗组1.9% vs 未治疗组8.6%。
- 瑞典队列10年前列腺癌死亡率:CPG1为1.0%,CPG2治疗组2.2% vs 未治疗组2.7%,CPG3治疗组6.1% vs 未治疗组12.5%。
- 英国现代AS队列中位随访3.5年,仅6%(8/133)进展至CPG3。
- 进展预测因素为PSA密度≥0.15 ng/mL/mL和诊断时CPG2;无上述因素、仅有一个因素、两个因素均有的男性进展率分别为1%、8%和21%。
- 西班牙独立AS队列(n=143)中相应进展率分别为3%、10%和14%。
关键数值与推荐
- 以进展至CPG3作为硬终点。
- PSA密度≥0.15 ng/mL/mL和诊断时CPG2为进展预测因素。
临床怎么用
- 作者认为利用疾病预后可合理指导主动监测的纳入标准、终止触发和风险分层管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To test whether using disease prognosis can inform a rational approach to active surveillance (AS) for early prostate cancer. PATIENTS AND METHODS: We previously developed the Cambridge Prognostics Groups (CPG) classification, a five-tiered model that uses prostate-specific antigen (PSA), Grade Group and Stage to predict cancer survival outcomes. We applied the CPG model to a UK and a Swedish prostate cancer cohort to test differences in prostate cancer mortality (PCM) in men managed conservatively or by upfront treatment in CPG2 and 3 (which subdivides the intermediate-risk classification) vs CPG1 (low-risk). We then applied the CPG model to a contemporary UK AS cohort, which was optimally characterised at baseline for disease burden, to identify predictors of true prognostic progression. Results were re-tested in an external AS cohort from Spain. RESULTS: In a UK cohort (n = 3659) the 10-year PCM was 2.3% in CPG1, 1.5%/3.5% in treated/untreated CPG2, and 1.9%/8.6% in treated/untreated CPG3. In the Swedish cohort (n = 27 942) the10-year PCM was 1.0% in CPG1, 2.2%/2.7% in treated/untreated CPG2, and 6.1%/12.5% in treated/untreated CPG3. We then tested using progression to CPG3 as a hard endpoint in a modern AS cohort (n = 133). During follow-up (median 3.5 years) only 6% (eight of 133) progressed to CPG3. Predictors of progression were a PSA density ≥0.15 ng/mL/mL and CPG2 at diagnosis. Progression occurred in 1%, 8% and 21% of men with neither factor, only one, or both, respectively. In an independent Spanish AS cohort (n = 143) the corresponding rates were 3%, 10% and 14%, respectively. CONCLUSION: Using disease prognosis allows a rational approach to inclusion criteria, discontinuation triggers and risk-stratified management in AS.
引用
- Gnanapragasam VJ, Barrett T, Thankapannair V, et al. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU Int. 2019. PMID: 31063245. doi:10.1111/bju.14800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。